Private Equity Healthcare Deals Slump as States Tighten Review

Statehouses are now setting the pace for healthcare deals

Private equity's healthcare dealmaking is now governed by a growing set of state rules. These rules no longer stop at asking for notice before a hospital merger. They also reach the structures sponsors use to buy, grow and sell physician practices. Data released in August suggests the effect has moved past compliance memos and into deal counts.

Private equity deal count in healthcare services fell nearly 19% in the second quarter of 2026 from a year earlier, PitchBook found. The physician practice management (PPM) segment is on track to fall 46% for the full year.23 PPM deal volume peaked at 851 transactions in 2021 and dropped to 105 in the first half of 2026.22 Deal value in the first half came to $17.8 billion, compared with an annual average of $62.8 billion since 2018.23

The coverage broadly agrees on the cause. PitchBook's analysts told reporters that new state laws and regulations make acquisitions slower and more expensive, and that they make roll-ups of small practices into larger platforms harder to carry out.13 PitchBook's lead healthcare analyst, Brian Wright, put it this way: the regulatory process takes longer, and no sponsor wants to be the first through a new one.23

What states actually changed

The term "oversight" now covers several different tools, and the differences matter for investors.

Notice and review. California's AB 1415 took effect January 1, 2026. It requires private equity groups, hedge funds and management services organizations (MSOs) to file their own notices with the Office of Health Care Affordability (OHCA). Before the law, they were only indirectly covered.18 Rhode Island's pre-merger rule for medical practice groups took effect January 28. It requires 60 days' notice before closing and carries fines of up to $100,000 for failing to file.19 Washington's expanded law took effect June 11 and covers changes of control, including those made through contracting affiliations.19 Oregon is still the strictest example. Its program requires 180 days' notice before closing, and a covered deal cannot close until the Oregon Health Authority has reviewed it.2

Corporate practice of medicine. California's SB 351 bars private equity groups and hedge funds from interfering with clinicians' professional judgment, including through MSOs.18 Oregon's SB 951 limits MSO ownership and de facto control over medical practices. It applies to new entities from January 2026, while existing arrangements have until January 1, 2029 to comply.8

Financial engineering. In 2026, the legislation began targeting how deals are paid for. Connecticut's SB 196, signed May 27, bans hospital sale-leasebacks. It also requires hospitals to attest every year that no private equity entity holds a controlling interest.14 Vermont's H. 583 was signed June 15. It limits control over clinical decisions by private equity groups, hedge funds and the MSOs they control, and it requires ownership disclosures by March 1, 2027.14 As introduced, the Vermont bill would have banned acquisitions financed with debt that becomes the healthcare entity's obligation, along with dividend structures of that kind.11

The Private Equity Stakeholder Project counts nine laws enacted in six states as of August 2026. In its view, the debate has moved from whether a hospital purchase should trigger notice to how control is exercised through MSOs, debt, real estate, joint ventures and parent entities.1

The tally depends on who is counting

The counts of how far this has spread vary, mostly because they measure different things. Stateline reports that at least 25 states have proposed or passed laws in recent years on healthcare transactions or on private equity's operating role.13 One industry roundup says at least 15 states have notice requirements specific to healthcare transactions. It also cites a National Conference of State Legislatures count of at least 35 states that require notice of some mergers, closures or affiliations.2 A law firm's end-of-session summary counts eight states that enacted transaction-related laws or regulations since January 1.6 These numbers do not conflict. They show that "oversight" ranges from simple notice filings to outright bans on certain structures.

The buyout math: time, cost and disclosure

For sponsors planning a buyout, timing is the most direct cost. Notice periods usually run 30 to 90 days. In California, Massachusetts and Oregon, a fuller review can push the wait to 180 days or longer.2 Under OHCA's process, review can last up to 250 days when a cost and market impact review is required.7

What must be disclosed may matter more than the delay. OHCA's emergency regulations implementing AB 1415 were approved October 2 and took effect immediately.7 The filing threshold for private equity is a 10% stake in a covered entity's assets, equity, debt or liabilities, or rights such as appointing leadership, vetoing decisions or arranging sale-leasebacks. Holland & Knight says this threshold would capture most platform acquisitions and sales and many minority investments.7 Sponsors must list the healthcare entities and MSOs their funds own or finance. They must also document debt-to-enterprise-value ratios and post-recapitalization leverage, and disclose executive compensation tied to the deal. These filings are public unless confidentiality is granted.7

That amounts to public disclosure of leverage, a central part of the leveraged buyout model. The California rules do not ban debt. They do mean every new deal's capital structure goes on record for regulators, competitors and critics.

The exit question

The exit side is where the reporting is thinnest and least consistent. Fierce Healthcare's account of PitchBook's second-quarter report says the 2026 exit count is on pace to fall 26.5% from 2025.23 A secondary summary of the same data describes 26.5% as the drop in overall deal count, which would be the lowest annual total since 2017.21 PitchBook's first-quarter report gave a different picture: exit count rose 6.7% year over year, even as exit value fell 17.9%.

My reading is that exits are holding up better than new platform formation, at least for now. The new rules work against the classic exit for practice platforms, though. A sponsor typically builds a regional roll-up through many small add-ons, then sells it to a bigger sponsor or a strategic buyer. Under the new regimes, those add-ons draw notice obligations even when they fall below federal Hart-Scott-Rodino thresholds.20 California's 10-year lookback for MSO transactions also means past deal activity stays relevant.7 Buyers will price that in. One industry analysis argues that valuations, exit timing and expansion plans now depend on regulatory exposure as much as on EBITDA.

The change is also lopsided. Bain counted a record roughly $191 billion in global healthcare private equity deal value in 2025, driven by large deals. Practice-level dealmaking, meanwhile, has shrunk.21 The first quarter of 2026 still produced large transactions, including General Atlantic's $3 billion buyout of TEAM Services Group. The rules land hardest on the small, frequent deals that roll-ups depend on.

Is regulation really the main cause?

The sources disagree on how much of the drop to blame on regulation. PitchBook describes state scrutiny as one reason among several.13 Wright also points to macroeconomic pressure and lower use of healthcare services. He speculates that lapsed ACA subsidies may have cut coverage and squeezed hospitals, which have historically been the largest strategic buyers of physician practices.23 PitchBook expects "mean reversion" and cites a rise in legal work on restructuring and cleanup, which usually comes before a sale.23

I think the regulatory effect is real but probably overstated as a single explanation. The sharpest decline is in PPMs, the segment most directly targeted by MSO and corporate-practice rules. That points to a real policy effect. The broad weakness across segments suggests the economy is also playing a large part. The case for a quick rebound is weaker, though. Regulators are not easing off, and the rules are aimed at the roll-up model itself.

Enforcement gaps and workarounds

On paper the rules are strict. In practice they have bitten less. Holland & Knight notes that OHCA has not historically used its reviews to block deals. Of 51 notices filed, only two went to a full cost and market impact review.7 Even Oregon, which requires consent, keeps approving private equity deals.7 In March it cleared Excellere's acquisition of SuperCare on the condition that the company keep participating in Medicaid and limit retail closures.10 Oregon's SB 951 has not yet been used to stop a private equity deal. The Oregon Medical Association has also noted that the law relies on private lawsuits rather than enforcement by state agencies.26

Stateline has also reported that private equity may be able to get around state laws by partnering with nonprofit health systems.13 Supporters of these laws should expect that kind of structural workaround.

Federal pressure, state persistence

On September 16, Democratic lawmakers led by Senators Elizabeth Warren, Ron Wyden and Jeff Merkley introduced the Stop Corporate Takeovers of Physicians Act. The bill is modeled on Oregon's SB 951.12 It includes a private right of action with treble damages and a non-preemption clause that keeps stricter state laws in place.12 The bill has no Republican co-sponsors, so it faces long odds.27 Even so, the clause means states will remain the main battleground regardless of what Congress does.

More state action is coming. New York has proposed five years of post-closing reporting. Pennsylvania's HB 2115 would require 120 days' notice and set penalties of at least $100,000 per violation. Hawaii's SB 3175 could require legislative approval for some vertical deals.1911

For investors, the practical result is less a ban on healthcare private equity than higher costs for the roll-up model. Deals will still close, but sponsors will have to file publicly, carry less debt and plan their exits around the regulators in each state where they operate.